Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Drug Therapy in CKD Patients With HCV
NCT07770984Phase 3Not yet recruiting
- Sponsor
- Tanta University
- Start
- Sep 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
A Phase 3 trial of sofosbuvir, daclatasvir, paritaprevir, ombitasvir, ritonavir in hepatitis C virus infection, sponsored by Tanta University. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
sofosbuvirdaclatasvirparitaprevirombitasvirritonavir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT07770984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07770984.